Table 1. Tissue distribution of SLAM proteins and their ligands.
Figure 1. Different types of SLAM-specific immunotherapies. The figure shows different ways to target the SLAM family of receptors expressed on myeloma cells. The myeloma antigen can be targeted by monoclonal antibodies (mAb), antibody-drug conjugates (ADC), bispecific antibodies, specific T cells recognizing HLA/SLAM peptide complexes, and SLAM-specific chimeric antigen receptor (CAR) T cells.
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
